Routine vs. Additional Risk Minimisation Measures

Risk minimisation measures are what Part V of the RMP structure actually specifies, and they split into two categories worth distinguishing precisely, because the distinction reflects a genuine escalation in intervention, not just a difference in documentation. Routine risk minimisation measures are, essentially, the product label doing its normal job: warnings, precautions, contraindications, dosing guidance, and the product’s legal and pack-size status. Every marketed product has these by default — they’re the baseline, and for the large majority of identified and potential risks, a well-written label genuinely is sufficient.

Additional risk minimisation measures are deployed specifically when the Safety Specification identifies a risk that the organisation judges routine measures alone won’t adequately manage — and they represent active intervention beyond passive information, things like targeted healthcare professional educational materials, restricted distribution or prescriber certification requirements before a drug can even be prescribed, or structured patient monitoring programmes that require ongoing participation from the healthcare system, not just awareness.

This escalation isn’t applied casually, and understanding why matters as much as knowing the categories exist. Additional measures impose genuine, real-world burden — on prescribers who now have to complete certification, on patients who now face restricted access or mandatory monitoring visits, on healthcare systems that have to build and maintain the infrastructure to support the measure at all. That burden needs to be proportionate to, and justified by, the severity and nature of the specific risk being managed — which is exactly why the decision to require an additional measure flows directly from the Safety Specification’s risk categorisation covered in the previous lesson, rather than being applied reflexively to every identified risk regardless of severity.

And because additional measures carry real cost and burden, they don’t simply get imposed and left unexamined — Lesson 9.7 covers how organisations are specifically expected to evaluate whether an additional measure is actually achieving its intended effect, precisely because a measure that imposes real burden without measurably reducing risk isn’t serving its purpose, and that evaluation is treated as an ongoing obligation, not a one-time justification made at the time the measure was first introduced.